Carvedilol in antihypertensive therapy – experience of Warsaw center Case report
Article Sidebar
Main Article Content
Abstract
Carvedilol is a non-selective β-blocker that has vasodilating properties by blocking α1-adrenergic receptors. The hypotensive effect of the drug is due not only to the negative chronotropic effects, but also to the reduction in peripheral vascular resistance. Carvedilol better than classic β-blockers lowers the central blood pressure and also has a beneficial effect on the metabolic and renal functions. Indications for carvedilol are hypertension in patients with tachycardia and/or arrhythmias, hyperkinetic circulation, particularly in younger patients, hypertension associated with heart failure, coronary artery disease, and post myocardial infarction. Carvedilol should be preferred as a hypotensive drug in patients with associated diabetes mellitus, metabolic syndrome and impaired renal function.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
3. Wright J.T. Jr, Bakris G.L., Bell D.S. et al.: Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J. Clin. Hypertens. (Greenwich) 2007; 9(11): 842-849.
4. Jacob S., Rett K., Henriksen E.J.: Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am. J. Hypertens. 1998; 11(10): 1258-1265.
5. Giugliano D., Acampora R., Marfella R.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. 1997; 126(12): 955-959.
6. Hauf-Zachariou U., Widmann L., Zülsdorf B. et al.: A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur. J. Clin. Pharmacol. 1993; 45(2): 95-100.
7. Galzerano D., Tammaro P., del Viscovo L. et al.: Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass. A multicenter, randomized, longitudinal study. Am. J. Hypertens. 2005; 18(12 Pt 1): 1563-1569.